Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Hematology · Systemic Mastocytosis

The Subtypes & Risk: Understanding Your Diagnosis

At a Glance

Systemic mastocytosis is categorized into subtypes based on disease burden (B-findings) and organ damage (C-findings). Indolent and smoldering SM are non-advanced forms, while aggressive SM, SM-AHN, and mast cell leukemia are advanced forms requiring active treatment to protect organ function.

Once a diagnosis of Systemic Mastocytosis (SM) is confirmed, the next step is determining the subtype. Subtypes describe how the disease is behaving and how many mast cells are in the body [1]. To understand this risk, doctors use a stratification model based on B-findings and C-findings [2].

  • B-findings represent a high Burden of mast cells in the body [3]. While the cells are numerous, they have not yet caused significant damage to your organs [2].
  • C-findings represent the need for Cytoreduction (treatment to kill mast cells) because they are causing measurable organ damage [4].

Measuring Disease Burden: The B-Findings

If you have a high level of mast cells but your organs are still functioning normally, you may have one or more B-findings. These include [3][4][5]:

  1. High Bone Marrow Infiltration: Over 30% of the cells in your bone marrow are abnormal mast cells.
  2. Elevated Serum Tryptase: A baseline tryptase level consistently above 200 ng/mL.
  3. Organ Enlargement (without failure): An enlarged liver (hepatomegaly) or spleen (splenomegaly) that is not yet causing abnormal liver enzymes or blood count issues.

Identifying Organ Damage: The C-Findings

C-findings are serious markers that indicate the mast cells are interfering with how your body works. Identifying even one C-finding can shift a diagnosis to Aggressive Systemic Mastocytosis (ASM) [2][4]. Key C-findings include [6][7][8]:

  • Cytopenias (Low Blood Counts): The mast cells in the marrow are crowding out healthy blood cells, leading to severe drops in hemoglobin, platelets, or neutrophils.
  • Liver Impairment: Signs of liver stress like fluid in the abdomen (ascites), portal hypertension, or actual liver failure [6][4].
  • Skeletal Lesions: Large areas of bone destruction (osteolysis) that can lead to “pathologic fractures” [4].
  • Malabsorption: Significant weight loss caused by mast cells infiltrating the gastrointestinal tract and preventing you from absorbing nutrients [9][10].

The Subtypes of Systemic Mastocytosis

Doctors use your B and C findings to place you into a specific subtype [4][5][11].

Indolent and Smoldering SM (Non-Advanced)

Most adults have “non-advanced” forms of the disease. These are typically managed by treating symptoms and, increasingly, using targeted therapies [12].

  • Indolent SM (ISM): The most common subtype [13]. Patients have 0 or 1 B-findings and no C-findings. Mast cells are present, but not causing organ damage. Most patients with ISM have a normal life expectancy [14].
  • Smoldering SM (SSM): An intermediate form. Patients must have at least two B-findings AND the complete absence of any C-findings [15][16]. There is a higher risk of the disease progressing over time [17].

Advanced Systemic Mastocytosis (AdvSM)

In advanced forms, the mast cells interfere with how your organs function.

  1. Aggressive SM (ASM): Defined by the presence of at least one C-finding, showing measurable organ damage [18]. Active treatment to reduce mast cell burden is required [19].
  2. SM-AHN / SM-AMN: In this subtype, a patient has systemic mastocytosis plus a second, distinct blood disorder (an Associated Hematologic or Myeloid Neoplasm) [18][20]. You may see this written as SM-AMN under the newer 2022 WHO/ICC guidelines [21].
  3. Mast Cell Leukemia (MCL): The most rare and aggressive form, diagnosed when mast cells make up 20% or more of the cells in a bone marrow aspirate smear [22][23].

Understanding where you fall on this spectrum is empowering. It maps directly to your Treatments and Targeted Therapies, moving you beyond “having mastocytosis” to a concrete, personalized management plan.

Common questions in this guide

What are B-findings in systemic mastocytosis?
B-findings indicate a high burden of mast cells in your body, but they are not yet causing measurable organ damage. Examples include having over 30% abnormal mast cells in your bone marrow or a baseline tryptase level consistently above 200 ng/mL.
What are C-findings in systemic mastocytosis?
C-findings are serious medical markers showing that mast cells are actively damaging your organs. These findings can include severe low blood counts, liver impairment, large bone lesions, or significant weight loss from poor nutrient absorption.
What is the difference between indolent and smoldering systemic mastocytosis?
Indolent systemic mastocytosis is the most common form, featuring zero or one B-finding and no organ damage. Smoldering systemic mastocytosis is an intermediate form where a patient has at least two B-findings, but still no signs of organ damage.
What makes systemic mastocytosis aggressive?
Systemic mastocytosis is classified as aggressive when there is at least one C-finding present. This indicates that the excessive mast cells are interfering with normal organ function and that active treatment is required.
What does an SM-AHN or SM-AMN diagnosis mean?
SM-AHN (or SM-AMN) occurs when a patient has systemic mastocytosis along with a second, completely separate blood disorder. Both conditions exist simultaneously in the bone marrow and require a specialized management approach.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific subtype of systemic mastocytosis do I have, and what led to that classification?
  2. 2.Do I have any 'B-findings' that suggest a high mast cell burden, even if my organs are functioning normally?
  3. 3.Are there any 'C-findings' in my labs or imaging that would classify my condition as 'advanced' or 'aggressive'?
  4. 4.Was there any evidence of an 'associated hematologic/myeloid neoplasm' (AHN/AMN) in my bone marrow?
  5. 5.How often should we repeat my imaging or blood tests to monitor for the development of new B or C findings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Medical algorithm: Peri-operative management of mastocytosis patients.

    Bocca-Tjeertes IFA, van de Ven AAJM, Koppelman GH, et al.

    Allergy 2021; (76(10)):3233-3235 doi:10.1111/all.14891.

    PMID: 33948959
  2. 2

    The international consensus classification of eosinophilic disorders and systemic mastocytosis.

    Wang SA, Orazi A, Gotlib J, et al.

    American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

    PMID: 37283522
  3. 3

    Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

    Valent P, Akin C, Hartmann K, et al.

    HemaSphere 2021; (5(11)):e646 doi:10.1097/HS9.0000000000000646.

    PMID: 34901755
  4. 4

    Review and Updates on Systemic Mastocytosis and Related Entities.

    Li JY, Ryder CB, Zhang H, et al.

    Cancers 2023; (15(23)) doi:10.3390/cancers15235626.

    PMID: 38067330
  5. 5

    Diagnosing Systemic Mastocytosis: State of the Art.

    Rets A, George TI

    International journal of laboratory hematology 2025; doi:10.1111/ijlh.70011.

    PMID: 41058066
  6. 6

    Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.

    Hartmann K, Gotlib J, Akin C, et al.

    The Journal of allergy and clinical immunology 2020; (146(2)):356-366.e4 doi:10.1016/j.jaci.2020.03.044.

    PMID: 32437738
  7. 7

    Aggressive Systemic Mastocytosis Presenting as Pyrexia of Unknown Origin and Sclerotic Bone Lesions: An Uncommon Presentation of a Rare Haematological Disorder.

    Ismail U, Fatima SA

    Cureus 2025; (17(9)):e92162 doi:10.7759/cureus.92162.

    PMID: 40949069
  8. 8

    Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis.

    Bonifacio M, Zanotti R, Guardalben E, et al.

    Clinical case reports 2017; (5(12)):1988-1991 doi:10.1002/ccr3.1232.

    PMID: 29225841
  9. 9

    Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach.

    Zanelli M, Pizzi M, Sanguedolce F, et al.

    Cancers 2021; (13(13)) doi:10.3390/cancers13133316.

    PMID: 34282774
  10. 10

    Gastrointestinal Involvement in Mast Cell Activation Disorders.

    Hsieh FH

    Immunology and allergy clinics of North America 2018; (38(3)):429-441 doi:10.1016/j.iac.2018.04.008.

    PMID: 30007461
  11. 11

    Endocrine manifestations of systemic mastocytosis in bone.

    Greene LW, Asadipooya K, Corradi PF, Akin C

    Reviews in endocrine & metabolic disorders 2016; (17(3)):419-431 doi:10.1007/s11154-016-9362-3.

    PMID: 27239674
  12. 12

    Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.

    Zanotti R, Bonifacio M, Lucchini G, et al.

    Leukemia 2022; (36(2)):516-524 doi:10.1038/s41375-021-01406-y.

    PMID: 34545185
  13. 13

    Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.

    Paiva ML, Yumeen S, Saliba E, DiMarco C

    JAAD case reports 2023; (36()):63-66 doi:10.1016/j.jdcr.2023.04.009.

    PMID: 37250010
  14. 14

    The international consensus classification of mastocytosis and related entities.

    Leguit RJ, Wang SA, George TI, et al.

    Virchows Archiv : an international journal of pathology 2023; (482(1)):99-112 doi:10.1007/s00428-022-03423-3.

    PMID: 36214901
  15. 15

    Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.

    Tefferi A, Shah S, Reichard KK, et al.

    American journal of hematology 2019; (94(1)):E1-E2 doi:10.1002/ajh.25302.

    PMID: 30281840
  16. 16

    Comprehensive mastocytosis data analysis from a single center.

    Tiryaki TO, Özkan SG, Erdem S, et al.

    BMC cancer 2023; (23(1)):82 doi:10.1186/s12885-022-10498-3.

    PMID: 36694141
  17. 17

    Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

    Castells M, Butterfield J

    The journal of allergy and clinical immunology. In practice 2019; (7(4)):1097-1106 doi:10.1016/j.jaip.2019.02.002.

    PMID: 30961835
  18. 18

    Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.

    Tashi T, Deininger MW

    Immunology and allergy clinics of North America 2023; (43(4)):723-741 doi:10.1016/j.iac.2023.04.009.

    PMID: 37758409
  19. 19

    Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.

    DeAngelo DJ, Radia DH, George TI, et al.

    Nature medicine 2021; (27(12)):2183-2191 doi:10.1038/s41591-021-01538-9.

    PMID: 34873347
  20. 20

    Evolution of myelodisplasic syndrome with ring sideroblasts (MDS-RS) to systemic mastocytosis and aleukemic mast cell leukemia.

    Costa LD, Azambuja AP, Ângelo Lisboa ES, et al.

    Hematology, transfusion and cell therapy 2020; (42(4)):387-389 doi:10.1016/j.htct.2019.08.003.

    PMID: 31801702
  21. 21

    Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.

    Aperna F, Abdelmagid MG, Kumar M, et al.

    American journal of hematology 2025; (100(9)):1566-1576 doi:10.1002/ajh.27764.

    PMID: 40607735
  22. 22

    Mast Cell Leukemia: An Update with a Practical Review.

    Zanelli M, Quintini M, Magnasco S, et al.

    Cancers 2023; (15(6)) doi:10.3390/cancers15061664.

    PMID: 36980550
  23. 23

    Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.

    Tefferi A, Abdelmagid M, Al-Kali A, et al.

    American journal of hematology 2024; (99(1)):21-27 doi:10.1002/ajh.27113.

    PMID: 37772442

This page explains systemic mastocytosis subtypes and risk classifications for educational purposes only. Always consult your hematologist or oncologist for an accurate diagnosis and interpretation of your specific laboratory results.

Get notified when new evidence is published on Mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.